Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th
Sight Sciences (Nasdaq: SGHT), an eyecare technology company specializing in innovative interventional technologies, has announced its participation in the 24th Annual Needham Healthcare Conference. The virtual event will feature a presentation by the company's management on April 8, 2025, at 12:45 PM PT / 3:45 PM ET.
Investors and interested parties can access both the live and archived versions of the fireside chat through the company's investor relations website at investors.sightsciences.com.
Sight Sciences (Nasdaq: SGHT), un'azienda tecnologica nel settore dell'eyecare specializzata in tecnologie interventistiche innovative, ha annunciato la sua partecipazione alla 24ª Conferenza Sanitaria Annuale Needham. L'evento virtuale presenterà un intervento da parte della direzione dell'azienda il 8 aprile 2025, alle 12:45 PT / 15:45 ET.
Gli investitori e le parti interessate possono accedere sia alla versione live che a quella registrata della chat informativa attraverso il sito web delle relazioni con gli investitori dell'azienda all'indirizzo investors.sightsciences.com.
Sight Sciences (Nasdaq: SGHT), una empresa de tecnología en el cuidado ocular que se especializa en tecnologías intervencionistas innovadoras, ha anunciado su participación en la 24ª Conferencia Anual de Salud Needham. El evento virtual contará con una presentación por parte de la dirección de la empresa el 8 de abril de 2025, a las 12:45 PM PT / 3:45 PM ET.
Los inversores y partes interesadas pueden acceder tanto a la versión en vivo como a la grabada de la charla a través del sitio web de relaciones con inversores de la empresa en investors.sightsciences.com.
사이트 사이언스 (Nasdaq: SGHT), 혁신적인 개입 기술에 전문화된 안과 기술 회사가 제24회 니드햄 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 이 가상 이벤트에서는 회사 경영진의 발표가 2025년 4월 8일 오후 12:45 PT / 오후 3:45 ET에 있을 예정입니다.
투자자 및 관심 있는 분들은 회사의 투자자 관계 웹사이트인 investors.sightsciences.com을 통해 라이브 및 아카이브된 화상 채팅을 모두 이용할 수 있습니다.
Sight Sciences (Nasdaq: SGHT), une entreprise technologique spécialisée dans les soins oculaires et les technologies d'intervention innovantes, a annoncé sa participation à la 24e Conférence Annuelle de Needham sur la Santé. L'événement virtuel comprendra une présentation de la direction de l'entreprise le 8 avril 2025, à 12h45 PT / 15h45 ET.
Les investisseurs et les parties intéressées peuvent accéder aux versions en direct et enregistrées de la discussion via le site web des relations investisseurs de l'entreprise à l'adresse investors.sightsciences.com.
Sight Sciences (Nasdaq: SGHT), ein technologieunternehmen im Bereich Augenheilkunde, das sich auf innovative interventionelle Technologien spezialisiert hat, hat seine Teilnahme an der 24. jährlichen Needham Healthcare-Konferenz bekannt gegeben. Die virtuelle Veranstaltung wird eine Präsentation des Unternehmensmanagements am 8. April 2025 um 12:45 Uhr PT / 15:45 Uhr ET beinhalten.
Investoren und Interessierte können sowohl auf die Live- als auch auf die archivierte Version des Fireside Chats über die Investor-Relations-Website des Unternehmens unter investors.sightsciences.com zugreifen.
- None.
- None.
MENLO PARK, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the 24th Annual Needham Healthcare Conference being held virtually.
Sight Sciences’ management is scheduled to present on Tuesday, April 8, 2025, at 12:45 pm PT / 3:45 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the Company’s website at https://investors.sightsciences.com/.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (“MGD”), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
© 2025 Sight Sciences. All rights reserved.
Media contact:
pr@sightsciences.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
investor.relations@sightsciences.com
FAQ
When is Sight Sciences (SGHT) presenting at the Needham Healthcare Conference 2025?
How can investors watch Sight Sciences' (SGHT) Needham Conference presentation?
Is the 2025 Needham Healthcare Conference where SGHT is presenting in-person or virtual?
What type of presentation will SGHT deliver at the 2025 Needham Conference?
